US2003036553A1PendingUtilityA1

Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis

40
Priority: May 25, 2000Filed: Aug 13, 2002Published: Feb 20, 2003
Est. expiryMay 25, 2020(expired)· nominal 20-yr term from priority
Inventors:Richard ScheyerStephen M. SorensenJanice Hitchcock
A61P 25/24A61P 25/00A61P 25/20A61P 25/28A61K 31/445A61P 25/16
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug (Formula II) in treating patients for symptoms of dementia and dopamine induced psychosis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating the behavioral, psychological or motor symptoms of dementia by administering to a patient having dementia a therapeutically effective amount of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, or a pharmaceutically acceptable salt thereof; or a prodrug, its stereoisomer or pharmaceutically acceptable salt thereof, wherein the prodrug is  
       
         
           
           
               
               
           
         
       
       wherein R is C 1 -C 20  alkyl.  
     
     
         2 . The method of  claim 1  wherein the symptom is a behavioral symptom.  
     
     
         3 . The method of  claim 2  wherein the behavioral symptom is aggression.  
     
     
         4 . The method of  claim 2  wherein the behavioral symptom is sleep disturbances.  
     
     
         5 . The method of  claim 1  wherein the symptoms are psychological symptoms.  
     
     
         6 . The method of  claim 5  wherein the psychological symptom is hallucinations.  
     
     
         7 . The method of  claim 5  wherein the psychological symptom is delusions.  
     
     
         8 . The method of  claim 5  wherein the psychological symptom is depression.  
     
     
         9 . The method of  claim 1  wherein the symptom is a motor symptom.  
     
     
         10 . The method of  claim 1  wherein the dementia is Lewy body dementia.  
     
     
         11 . The method of  claim 1  wherein the dementia is Alzheimer's disease.  
     
     
         12 . The method of  claim 2  wherein the dementia is dementia in Parkinson's disease.  
     
     
         13 . The method of  claim 1  wherein R is C 5 -C 20 .  
     
     
         14 . The method of  claim 1  wherein R is Cg.  
     
     
         15 . The method of  claim 1  wherein a therapeutically effective amount of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof is administered to the patient.  
     
     
         16 . The method of  claim 1  wherein a therapeutically effective amount of the prodrug, its stereoisomer or a pharmaceutically acceptable salt thereof is administered to the patient.  
     
     
         17 . A method of treating dopamine induced psychosis by administering to a patient having dopamine induced psychosis a therapeutically effective amount of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, or a pharmaceutically acceptable salt thereof; or a prodrug, its stereoisomer or pharmaceutically acceptable salt thereof, wherein the prodrug is  
       
         
           
           
               
               
           
         
       
       wherein R is C 1 -C 20  alkyl.  
     
     
         18 . The method of  claim 17  wherein R is C 5 -C 20 .  
     
     
         19 . The method of  claim 17  wherein R is C 9 .

Join the waitlist — get patent alerts

Track US2003036553A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.